Healthcare

1. Competitive Intelligence

IeB provides valuable insights by thoroughly analyzing competitors’ internal processes, strategies, strengths, weaknesses, and market positioning. We conduct market research, benchmarking, and analysis of industry trends to equip clients with the information they need to make informed decisions and stay competitive in their market space.

We go beyond surface-level analysis to comprehensively assess competitors’ strategies and capabilities. Our in-depth analysis covers both approved and pipeline drugs. We offer detailed insights into the market’s competitive intensity and unmet needs by performing pipeline assessment and clinical trial analysis. This is instrumental in formulating current and future strategies, keeping you competitive and up to date with market trends.

4. Disease Landscape Opportunity Assessment

Venturing into a new therapeutic area requires a comprehensive market opportunity assessment and understanding of unmet needs. Thus, we focus on several areas, including disease pathophysiology, epidemiology, market assessment, and stakeholder discussions, to aid in market sizing, identifying gaps in the market, and understanding the key market trends.

IeB supports developing a thorough perspective of different drug development programs, providing data on the current competitive landscape and key focus areas of interest. We identify the key market dynamics, encompassing clinical trial designs of late-stage molecules, and aid clients in various development strategies. Our Disease Landscape Assessment and Situational Analysis provide an overall perspective of the current and futuristic market view for supporting clients in better strategic planning and decision-making. In this, we also cover:

• Market Sizing and Epidemiology
• Competitive Landscape Analysis
• Patient Journey Mapping
• Treatment Landscape Assessment
• Strategic Scenario Planning
• Value Proposition Development

2. Market Access

In market access, we offer a holistic view of the entire market access ecosystem of the reimbursement and cost-and-coverage dynamics that matter to stakeholders across the value chain. We have worked across diverse therapeutic areas and helped clients navigate the complex healthcare landscape, focusing solely on delivering value. IeB spectrum of services related to market access includes assessing pricing strategies, conducting cost-benefit analysis, analyzing reimbursement scenarios, and using Health Technology Assessments (HTAs) to determine drug pricing based on market conditions, competitor landscape, and payer requirements, ensuring broad patient access.

Through market access, Ingenious e-Brain supports its clients in:

• Navigating the reimbursement landscape and securing favorable coverage decisions on the formularies from the payers
• Identifying key stakeholders, such as payers, healthcare providers, and patient advocacy groups, and tailoring value propositions accordingly
• Engaging with policymakers and advocating for policies that support patient access to innovative therapies
• Navigating the evolving regulatory landscape and adapting market access strategies

5. Commercial Opportunity Assessment

IeB assists in enhancing pharmaceutical products’ success by anticipating market trends and preparing for challenges. Collaborating with clients, we create compelling business cases and robust forecasting models that consider competitors, adoption rates, and peak market share. Using various techniques, such as analog and attribute analysis, we compare new products to existing ones, factoring in Loss of Exclusivity (LOE) impacts. Sensitivity and scenario analyses identify key success drivers and risks.

• Our market assessment approach evaluates the competitive landscape, pricing, market size, and growth opportunities, providing detailed comparisons and KPIs.
• Our deal tracking approach monitors industry partnerships, offering insights and financial modeling to support strategic initiatives.
• Thorough competitive profiling delivers tailored competitor analysis, utilizing a blend of secondary and primary research.
• In commercial strategy and business development, we identify and evaluate licensing opportunities, recommend partners, and structure deals to drive growth, helping clients make informed decisions and optimize outcomes.

3. Support for M&A and Strategic Opportunities

Selecting the appropriate partner for growth and diversification is pivotal. IeB supports clients in this process by identifying suitable companies, initiating exploratory discussions to assess interest in potential collaborations, and facilitating introductions between our client and the prospective partner.

Our industry experts assist corporate development teams by conducting thorough due diligence on potential partners; providing insights into their capabilities, product portfolios, and strategic alignment. Our comprehensive approach includes:

• Identifying potential partners aligned with clients’ growth objectives
• Initiating preliminary discussions to gauge interest and feasibility
• Facilitating introductions to foster meaningful connections
• Conducting in-depth due diligence to assess partner capabilities and portfolios

Besides this, IeB works closely with clients to pinpoint potential collaborators with complementary synergies and strengths. We identify and evaluate partners with a strategic focus on in-licensing and out-licensing collaborations involving New Chemical Entities (NCEs) and formulations. This collaborative effort aims to uncover fresh market prospects and strategically allocate resources to address portfolio gaps effectively.

6. Product Lifecycle Assessment

Effective Product Lifecycle Management (PLM) is essential for maintaining competitiveness and fostering continuous innovation to secure a company’s market position. At Ingenious e-Brain (IeB), we assist clients in understanding post-commercialization market dynamics and formulating strategies to enhance product profitability. This involves a comprehensive analysis of emerging markets, assessment of potential new indications, and development of strategies to manage Loss of Exclusivity (LOE) to ensure business growth while mitigating the impact of generic drugs.

Our expertise includes:

• Emerging Market Analysis: Identifying and evaluating growth opportunities in untapped markets.
• Indication Expansion: Strategically broadening product applications to increase market share.
• LOE Strategies: Creating robust plans to counteract the effects of patent expiration and generic competition.
• Profit Optimization: Implementing data-driven approaches to maximize profitability throughout the product lifecycle.

7. Brand Strategy

The evolution of communication now goes beyond raising awareness about diseases and drugs to actively educating and shaping perceptions about new products. IeB collaborates with clients to recognize target customer segments and craft a unique brand positioning and identity through thorough research. We assist in highlighting essential Unique Selling Points (USPs) and establishing a distinct market presence through a strong brand strategy and communication plan that resonates with key stakeholders, ensuring lasting recall. Additionally, we design campaigns, activities, and promotional messages that are not only measurable but also easily executable.

8. Product Value Proposition

Assessing the viewpoints of Patients, Payers, and Providers plays a fundamental role in defining a distinctive Value Proposition or Target Product Profile (TPP) for a drug during its development phase. By evaluating the patient experience and key stakeholder environment to pinpoint unmet needs, benchmarking competitors’ product attributes, and corroborating with internal preclinical data to establish a value proposition, we can construct scenarios around the TPP. This process enables us to gauge prescriber preferences and anticipate market adoption during the product launch.

9. Real World Evidence Studies

Timely clinical evidence data, which delves into a drug’s utilization, advantages, and potential risks or adverse reactions, is vital for post-market surveillance studies and broadening indications for various diseases or subgroups. Therefore, it is important to analyze real-world data from third-party databases, yielding valuable insights into product efficacy, unmet needs, and the cost-benefit ratio. This is where IeB comes into play.